Arginine-Rich Manganese Silicate Nanobubbles as a Ferroptosis-Inducing Agent for Tumor-Targeted Theranostics

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Research

Background:

• Ferroptosis, an iron-dependent cell death, shows promise for cancer therapy.
• Current iron-based nanomaterials induce ferroptosis via ROS generation (Fenton reaction).
• A novel approach is needed to enhance ferroptosis induction and cancer treatment.

Purpose of the Study:

• To develop arginine-rich manganese silicate nanobubbles (AMSNs) as a novel ferroptosis-inducing agent.
• To investigate AMSNs' ability to deplete glutathione (GSH) and inactivate GPX4 for ferroptosis.
• To evaluate AMSNs for tumor-targeted therapy, including MRI enhancement and drug delivery.

Main Methods:

• Synthesis of AMSNs using a one-pot reaction with arginine as a surface ligand.
• Assessment of GSH depletion capability and GPX4 inactivation by AMSNs.
• Evaluation of tumor suppression, T1-weighted MRI enhancement, and chemotherapeutic drug release in vitro and in vivo.

Main Results:

• AMSNs efficiently depleted GSH, leading to GPX4 inactivation and ferroptosis.
• Arginine coating facilitated tumor homing of AMSNs.
• AMSN degradation enabled MRI enhancement and controlled drug release for synergistic therapy.

Conclusions:

• GSH depletion-induced ferroptosis using manganese-based nanomaterials is a viable cancer therapy strategy.
• AMSNs demonstrate potential as theranostic nanomedicines for targeted cancer treatment.
• This approach offers insights for designing novel nanomedicines for tumor-targeted theranostics.